目录
关闭
更新日期：2025年10月10日
姓 名 张小勇 性 别 男
民 族 汉族 导师层次 博士导师
技术职称 教授 导师类型 学术&专业型
最后学历 博士研究生毕业 最后学位 医学博士学位
行政职务 Email xiaoyzhang@smu.edu.cn
工作单位 南方医科大学南方医院 邮政编码 510515
个人简介

南方医科大学南方医院感染内科主任医师、教授、博士生导师、博士后合作导师，中华医学会感染病学分会青年委员会副主任委员，华中科技大学同济医学院医学博士，德国杜伊斯堡-埃森大学医学博士、博士后。主要致力于乙肝病毒免疫致病机制和抗病毒治疗新药开发的研究。作为负责人承担国家自然科学基金青年和面上项目、“十四五”国家重点研发计划、“十三五”科技部传染病防治重大专项、广东省自然科学基金、广州市健康医疗协同创新重大专项子课题等10余项课题。入选广州市“珠江科技新星”、广东省“特支计划”青年拔尖人才和广东省杰出青年医学人才。研究成果在国内外期刊发表科研论文100余篇，其中第一和通讯作者SCI论文40余篇，总影响因子>150。研究成果多次受邀在国际肝病会议和国际乙肝分子生物学会议等国际会议上口头汇报，多次获得欧洲肝病研究联合会（EASL）和亚太地区肝病联合会（APASL）的“青年科学家”奖励，参与获得广东省科技进步一等奖2项。

研究领域

长期从事慢性肝病基础研究及转化医学研究，主要研究方向为慢性乙型肝炎免疫致病机制及抗病毒治疗新靶标的筛选与临床开发，具体包括：1）宿主天然免疫通路蛋白调控乙肝病毒复制与基因表达的效应和机制研究；2）SMAC类似物治疗慢性乙肝感染的临床前研究及临床研究；3）基因工程T细胞治疗肝纤维化和肝癌的临床前研究。

 

个人成果
  1. 代表性论文：
    1. Qin Q, Zheng Y, Wang Y, Zhou F, Li D, Jin L, Zhu M, Guo Y, Fan R, Hou J, Zhang X, Liu H. Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors. Ther Adv Med Oncol. 2025 Jun 19;17:17588359251347469. doi: 10.1177/17588359251347469.
    2. Zhou Y, Zhao W, Zhu Y, Liu H, Sun Y, Gong Z, Li X, Liu Z, Wen K, Wang Y, Ren J, Xiao R, Jiang L, Hu Y, Bi E, Zhang X. CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD-1 Blockade. Adv Sci (Weinh). 2025 Jun 10:e08095. doi: 10.1002/advs.202508095.
    3. Zeng ZY, Huang ZX, Wang YR, Xie LK, Lin YP, Liang Y, Liu ZY, Li DL, Zhang XY. Anti-RPL30 as a novel biomarker for enhanced diagnosis of autoantibody-negative primary biliary cholangitis. World J Gastroenterol. 2025 May 28;31(20):104891. doi: 10.3748/wjg.v31.i20.104891.
    4. Liu Z, Li G, Li X, Wang Y, Liao L, Yang T, Han C, Huang K, Chen C, Li X, Liu H, Zhang X. CD163 impairs HBV clearance in mice by regulating intrahepatic T cell immune response via an IL-10-dependent mechanism. Antiviral Res. 2025 Jan 22;235:106093. doi: 10.1016/j.antiviral.2025.106093. Epub ahead of print. PMID: 39855274.
    5. Zhang H, Li X, Liu Z, Lin Z, Huang K, Wang Y, Chen Y, Liao L, Wu L, Xie Z, Hou J*, Zhang X*, Liu H*. Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc-ODC1 nexus. Cancer Metab. 2024 Feb 23;12(1):7. doi: 10.1186/s40170-024-00334-6.
    6. An Y, Zhang Q, Chen Y, Xia F, Wong YK, He H, Hao M, Tian J, Zhang X*, Luo P*, Wang J*. Chemoproteomics Reveals Glaucocalyxin A Induces Mitochondria-Dependent Apoptosis of Leukemia Cells via Covalently Binding to VDAC1. Adv Biol (Weinh). 2024 Feb;8(2):e2300538. doi: 10.1002/adbi.202300538. 
    7. Qin Q, Kou X, Zheng Y, Zhou F, Zhang X*, Liu H*. Early C-reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023 Nov 6;10:2009-2019. doi: 10.2147/JHC.S432054. eCollection 2023.
    8. Xie Z, Shen S, Huang K, Wang W, Liu Z, Zhang H, Lu M, Sun J, Hou J, Liu H*, Guo H*, Zhang X*. Mitochondrial HIGD1A inhibits hepatitis B virus transcription and replication through the cellular PNKD-NF-κB-NR2F1 nexus. J Med Virol. 2023 Apr;95(4):e28749. doi: 10.1002/jmv.28749.
    9. Huang K, Liu Z, Xie Z, Li X, Zhang H, Chen Y, Wang Y, Lin Z, Li C, Liu H*, Zhang X*. HIGD2A silencing impairs hepatocellular carcinoma growth via inhibiting mitochondrial function and the MAPK/ERK pathway. J Transl Med. 2023 Apr 12;21(1):253. doi: 10.1186/s12967-023-04105-7.
    10. Chen Q, Lu X, Xie J, Ma N, Xu W, Zhang Z, Huang X, Liu H, Hou J*, Zhang X*, Zhu W. * Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Front Oncol. 2022 Mar 31;12:813275. doi: 10.3389/fonc.2022.813275.
    11. Wu Y, Lu S, Huang X, Liu Y, Huang K, Liu Z, Xu W, Zhu W, Hou J, Liu H*, Zhang X*. Targeting cIAPs attenuates CCl4-induced liver fibrosis by increasing MMP9 expression derived from neutrophils. Life Sci. 2021 Dec 13:120235. doi: 10.1016/j.lfs.2021.120235.
    12. Xu W, Lu X, Liu J, Chen Q, Huang X, Huang K, Liu H*, Zhu W* and Zhang X*. Identification of PAFAH1B3 as Candidate Prognosis Marker and Potential Therapeutic Target for Hepatocellular Carcinoma. 19 August 2021, Front. Oncol. 11:700700. doi: 10.3389/fonc.2021.700700  6.244
    13. Lu X, Chen Q, Liu H, Zhang X. Interplay Between Non-Canonical NF-κB Signaling and Hepatitis B Virus Infection. Front Immunol. 2021 Sep 29;12:730684. doi: 10.3389/fimmu.2021.730684. eCollection 2021. 7.561
    14. Chen H, He G, Chen Y, Zhang X*. Hepatitis B Virus Might be Sensed by STING-Dependent DNA Sensors and Attenuates the Response of STING-Dependent DNA Sensing Pathway in Humans with Acute and Chronic Hepatitis B Virus Infection. Viral Immunol. 2020 Nov 10. doi: 10.1089/vim.2020.0096. Online ahead of print.
    15. Zhang X, Lu S, Li H, Wang Y, Lu Z, Liu Z, Lai Q, Ji Y, Huang X, Li Y, Sun J, Wu Y, Xu X, Hou J. Viral and Antibody Kinetics of COVID-19 Patients with Different 2 Disease Severities in Acute and Convalescent Phases: A 6-Month 3 Follow-Up Study. Virol Sin. 2020 Dec;35(6):820-829. doi: 10.1007/s12250-020-00329-9. Epub 2020 Dec 22.
    16. Chen Q, Lu X, Zhang X. The Non-canonical NF-kB signaling pathway in liver diseases. J Clin Transl Hepatol. 2021 Feb 28;9(1):81-89. doi: 10.14218/JCTH.2020.00063. Epub 2020 Dec 21.
    17. Zhu W, Liu H, Zhang X*. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection. ACS Infect Dis. 2019 May 10;5(5):703-712.
    18. Chen Z, Chen J, Liu H, Dong W, Huang X, Yang D, Hou J, Zhang X*. The SMAC mimetic APG-1387 sensitizes immune-mediated cell apoptosis in hepatocellular carcinoma Front Pharmacol. 2018 Nov 6;9:1298. doi: 10.3389/fphar.2018.01298.
    19. Liu H, Hou J, Zhang X*. Targeting cIAPs, A New Option for Functional Cure of Chronic Hepatitis B Infection? Virol Sin. 2018 Oct;33(5):459-461. doi: 10.1007/s12250-018-0062-x.
    20. Liu H#, Li F#, Zhang X#, Yu J, Wang J, Jia J, Yu X, Shen Z, Yuan Z, Zhang X, Zhang Z, Zhang X, Lu L, Li H, Lu M, Zhang J. Differentially expressed intrahepatic genes contribute to control of hepatitis B virus replication in the inactive carrier phase. J Infect Dis. 2018 Mar 13;217(7):1044-1054. doi: 10.1093/infdis/jix683.
    21. Liu C #, Huang X #, Werner M, Broering R, Ge J, Li Y, Liao B, Sun J, Peng J, Lu M, Hou J *, Zhang X *. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. Front Immunol. 2017 Mar 23;8:323. doi: 10.3389/fimmu.2017.00323.
    22. Huang Z#, Ge J#, Pang J, Liu H, Chen J, Liao B, Huang X, Zuo D, Sun J, Lu M, Zhang X *, Hou J *. Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. Antiviral Res. 2015 Jun;118:10-19. doi: 10.1016/j.antiviral.2015.03.004.
    23. Zhang X., Ma Z., Liu H., Liu J., Meng Z., Boering R., Yang D., Schlaak J., Roggendorf M., and Lu M, Role of Toll-like receptor 2 in the immune response against Hepadnavirus infection. J Hepatol. 2012, vol. 57, 522-528.
    24. Zhang X , Zhang E., Ma Z., Pei R., Jiang M., Schlaak J., Roggendorf M., and Lu M. Modulation of HBV Replication and Hepatocyte Differentiation by MicroRNA-1. Hepatology, 2011; 53(5):1476-1485.

 

2. 专利及其它：

用于治疗和/或预防与肝炎病毒相关的疾病和病症的双二氮杂双环化合物（专利号：ZL 2018 1 1381010.9）

环丙贝特在制备抗乙型肝炎病毒的药物中的应用 （专利号：ZL 2024 1 1152115.2）